Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity

Journal of Medicinal Chemistry

Volumn 59, Issue 19, 2016, Pages 8868-8878

  Azevedo, Carlos M G ^a   Watterson, Kenneth R ^b   Wargent, Ed T ^c   Hansen, Steffen V F ^a   Hudson, Brian D ^b   Kȩpczyńska, Małgorzata A ^c   Dunlop, Julia ^b   Shimpukade, Bharat ^a   Christiansen, Elisabeth ^a   Milligan, Graeme ^b   Stocker, Claire J ^c   Ulven, Trond ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF BUCKINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 BROMO 5 CHLOROPHENOXY)PYRIDINE; 2 (3 FLUORO 5 HYDROXYPHENYL) 2,3 DIHYDROBENZO[D]ISOTHIAZOLE 1,1 DIOXIDE; 2 (3 IODOPHENOXY)PYRIDINE; 2 (3 PHENOXYPHENYL) 2,3 DIHYDROBENZO[D]ISOTHIAZOLE 1,1 DIOXIDE; 2 (3 PHENOXYPHENYL)ISOTHIAZOLIDINE 1,1 DIOXIDE; 2 (4 HYDROXYPHENYL) 2,3 DIHYDROBENZO[D]ISOTHIAZOLE 1,1 DIOXIDE; 2 (4 PHENOXYPHENYL) 2,3 DIHYDROBENZO[D]ISOTHIAZOLE 1,1 DIOXIDE; 2 [3 (1,1 DIOXIDOBENZO[D]ISOTHIAZOL 2(3H) YL) 5 FLUOROPHENOXY]BENZONITRILE; 2 [3 (PYRIDIN 2 YLOXY)PHENYL] 2,3 DIHYDROBENZO[D]ISOTHIAZOLE 1,1 DIOXIDE; 2 [3 CHLORO 5 (PYRIDIN 2 YLOXY)PHENYL] 2,3 DIHYDROBENZO[D]ISOTHIAZOLE 1,1 DIOXIDE; 2 [3 FLUORO 5 (M TOLYLOXY)PHENYL] 2,3 DIHYDROBENZO[D]ISOTHIAZOLE 1,1 DIOXIDE; 2 [3 FLUORO 5 (O TOLYLOXY)PHENYL] 2,3 DIHYDROBENZO[D]ISOTHIAZOLE 1,1 DIOXIDE; 2 [3 FLUORO 5 (P TOLYLOXY)PHENYL] 2,3 DIHYDROBENZO[D]ISOTHIAZOLE 1,1 DIOXIDE; 2 [3 FLUORO 5 (PYRIDIN 2 YLOXY)PHENYL] 2,3 DIHYDROBENZO[D]ISOTHIAZOLE 1,1 DIOXIDE; 2 [3 [3 (1,1 DIOXIDOBENZO[D]ISOTHIAZOL 2(3H) YL) 5 FLUOROPHENOXY]PHENYL]ACETONITRILE; 3 [3 (1,1 DIOXIDOBENZO[D]ISOTHIAZOL 2(3H) YL) 5 FLUOROPHENOXY]BENZONITRILE; 4 [3 (1,1 DIOXIDOBENZO[D]ISOTHIAZOL 2(3H) YL) 5 FLUOROPHENOXY]BENZONITRILE; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CARBOXYLIC ACID DERIVATIVE; FREE FATTY ACID RECEPTOR 4 AGONIST; SULFONAMIDE; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; O3FAR1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG IDENTIFICATION; GLUCOSE TOLERANCE; HUMAN; IN VIVO STUDY; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLISM; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE MUTANT;

ANIMALS; CELL LINE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MICE; MICE, INBRED C57BL; MICE, OBESE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84991380589     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00685     Document Type: Article

References (39)

1. Offermanns, S. Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors Annu. Rev. Pharmacol. Toxicol. 2014, 54, 407-434 10.1146/annurev-pharmtox-011613-135945
2. Moniri, N. H. Free-fatty acid receptor-4 (GPR120): cellular and molecular function and its role in metabolic disorders Biochem. Pharmacol. 2016, 110-111, 1-15 10.1016/j.bcp.2016.01.021
3. Cornall, L. M.; Mathai, M. L.; Hryciw, D. H.; McAinch, A. J. GPR120 agonism as a countermeasure against metabolic diseases Drug Discovery Today 2014, 19, 670-679 10.1016/j.drudis.2013.11.021
4. Hara, T.; Kimura, I.; Inoue, D.; Ichimura, A.; Hirasawa, A. Free fatty acid receptors and their role in regulation of energy metabolism Rev. Physiol., Biochem. Pharmacol. 2013, 164, 77-116 10.1007/112-2013-13
5. Ulven, T.; Christiansen, E. Dietary Influences on Regulation of the Long-Chain Fatty Acid Receptor FFA4/GPR120 Annu. Rev. Nutr. 2015, 35, 239-263 10.1146/annurev-nutr-071714-034410
6. Milligan, G.; Alvarez-Curto, E.; Watterson, K. R.; Ulven, T.; Hudson, B. D. Characterising pharmacological ligands to study the long chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4 Br. J. Pharmacol. 2015, 172, 3254-3265 10.1111/bph.12879
7. Milligan, G.; Shimpukade, B.; Ulven, T.; Hudson, B. D. Complex Pharmacology of Free Fatty Acid Receptors. Chem. Rev. 2016, doi: 10.1021/acs.chemrev.6b00056.
8. Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; Miyazaki, S.; Tsujimoto, G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 Nat. Med. 2005, 11, 90-94 10.1038/nm1168
9. Paulsen, S. J.; Larsen, L. K.; Hansen, G.; Chelur, S.; Larsen, P. J.; Vrang, N. Expression of the fatty acid receptor GPR120 in the gut of diet-induced-obese rats and its role in GLP-1 secretion PLoS One 2014, 9, e88227 10.1371/journal.pone.0088227
10. Oh, D. Y.; Talukdar, S.; Bae, E. J.; Imamura, T.; Morinaga, H.; Fan, W. Q.; Li, P. P.; Lu, W. J.; Watkins, S. M.; Olefsky, J. M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects Cell 2010, 142, 687-698 10.1016/j.cell.2010.07.041
11. Ichimura, A.; Hirasawa, A.; Poulain-Godefroy, O.; Bonnefond, A.; Hara, T.; Yengo, L.; Kimura, I.; Leloire, A.; Liu, N.; Iida, K.; Choquet, H.; Besnard, P.; Lecoeur, C.; Vivequin, S.; Ayukawa, K.; Takeuchi, M.; Ozawa, K.; Tauber, M.; Maffeis, C.; Morandi, A.; Buzzetti, R.; Elliott, P.; Pouta, A.; Jarvelin, M.-R.; Korner, A.; Kiess, W.; Pigeyre, M.; Caiazzo, R.; Van Hul, W.; Van Gaal, L.; Horber, F.; Balkau, B.; Levy-Marchal, C.; Rouskas, K.; Kouvatsi, A.; Hebebrand, J.; Hinney, A.; Scherag, A.; Pattou, F.; Meyre, D.; Koshimizu, T.-a.; Wolowczuk, I.; Tsujimoto, G.; Froguel, P. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human Nature 2012, 483, 350-354 10.1038/nature10798
12. Oh, D. Y.; Walenta, E.; Akiyama, T. E.; Lagakos, W. S.; Lackey, D.; Pessentheiner, A. R.; Sasik, R.; Hah, N.; Chi, T. J.; Cox, J. M.; Powels, M. A.; Di Salvo, J.; Sinz, C.; Watkins, S. M.; Armando, A. M.; Chung, H.; Evans, R. M.; Quehenberger, O.; McNelis, J.; Bogner-Strauss, J. G.; Olefsky, J. M. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice Nat. Med. 2014, 20, 942-947 10.1038/nm.3614
13. Engelstoft, M. S.; Park, W. M.; Sakata, I.; Kristensen, L. V.; Husted, A. S.; Osborne-Lawrence, S.; Piper, P. K.; Walker, A. K.; Pedersen, M. H.; Nohr, M. K.; Pan, J.; Sinz, C. J.; Carrington, P. E.; Akiyama, T. E.; Jones, R. M.; Tang, C.; Ahmed, K.; Offermanns, S.; Egerod, K. L.; Zigman, J. M.; Schwartz, T. W. Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells Mol. Metab. 2013, 2, 376-392 10.1016/j.molmet.2013.08.006
14. Suckow, A. T.; Polidori, D.; Yan, W.; Chon, S.; Ma, J. Y.; Leonard, J.; Briscoe, C. P. Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion J. Biol. Chem. 2014, 289, 15751-15763 10.1074/jbc.M114.568683
15. Stone, V. M.; Dhayal, S.; Brocklehurst, K. J.; Lenaghan, C.; Sorhede Winzell, M.; Hammar, M.; Xu, X.; Smith, D. M.; Morgan, N. G. GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans Diabetologia 2014, 57, 1182-1191 10.1007/s00125-014-3213-0
16. Egerod, K. L.; Engelstoft, M. S.; Lund, M. L.; Grunddal, K. V.; Zhao, M.; Barir-Jensen, D.; Nygaard, E. B.; Petersen, N.; Holst, J. J.; Schwartz, T. W. Transcriptional and Functional Characterization of the G Protein-Coupled Receptor Repertoire of Gastric Somatostatin Cells Endocrinology 2015, 156, 3909-3923 10.1210/EN.2015-1388
17. Christiansen, E.; Watterson, K. R.; Stocker, C. J.; Sokol, E.; Jenkins, L.; Simon, K.; Grundmann, M.; Petersen, R. K.; Wargent, E. T.; Hudson, B. D.; Kostenis, E.; Ejsing, C. S.; Cawthorne, M. A.; Milligan, G.; Ulven, T. Activity of dietary fatty acids on FFA1 and FFA4 and characterization of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases Br. J. Nutr. 2015, 113, 1677-1688 10.1017/S000711451500118X
18. Shimpukade, B.; Hudson, B. D.; Hovgaard, C. K.; Milligan, G.; Ulven, T. Discovery of a Potent and Selective GPR120 Agonist J. Med. Chem. 2012, 55, 4511-4515 10.1021/jm300215x
19. Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Merten, N.; Pfleiderer, M.; Karlsen, K. K.; Rasmussen, S. S.; Steensgaard, M.; Hamacher, A.; Schmidt, J.; Drewke, C.; Petersen, R. K.; Kristiansen, K.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Ulven, T. Structure-activity study of dihydrocinnamic acids and discovery of the potent FFA1 (GPR40) agonist TUG-469 ACS Med. Chem. Lett. 2010, 1, 345-349 10.1021/ml100106c
20. Hudson, B. D.; Shimpukade, B.; Mackenzie, A. E.; Butcher, A. J.; Pediani, J. D.; Christiansen, E.; Heathcote, H.; Tobin, A. B.; Ulven, T.; Milligan, G. The Pharmacology of TUG-891, a Potent and Selective Agonist of the Free Fatty Acid Receptor 4 (FFA4/GPR120), Demonstrates Both Potential Opportunity and Possible Challenges to Therapeutic Agonism Mol. Pharmacol. 2013, 84, 710-725 10.1124/mol.113.087783
21. Arakawa, K.; Nishimura, T.; Sugimoto, Y.; Takahashi, H.; Shimamura, T. Preparation of heteroaryloxyphenyldihydrobenzisothiazoledioxide derivatives and analogs for use as GPR120 receptor modulators. WO2010104195A1, 2010.
22. Sparks, S. M.; Chen, G.; Collins, J. L.; Danger, D.; Dock, S. T.; Jayawickreme, C.; Jenkinson, S.; Laudeman, C.; Leesnitzer, M. A.; Liang, X.; Maloney, P.; McCoy, D. C.; Moncol, D.; Rash, V.; Rimele, T.; Vulimiri, P.; Way, J. M.; Ross, S. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120) Bioorg. Med. Chem. Lett. 2014, 24, 3100-3103 10.1016/j.bmcl.2014.05.012
23. Christiansen, E.; Urban, C.; Merten, N.; Liebscher, K.; Karlsen, K. K.; Hamacher, A.; Spinrath, A.; Bond, A. D.; Drewke, C.; Ullrich, S.; Kassack, M. U.; Kostenis, E.; Ulven, T. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA1/GPR40), a potential target for the treatment of type II diabetes J. Med. Chem. 2008, 51, 7061-7064 10.1021/jm8010178
24. Hudson, B. D.; Shimpukade, B.; Milligan, G.; Ulven, T. The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120) J. Biol. Chem. 2014, 289, 20345-20358 10.1074/jbc.M114.561449
25. Shelley, J. C.; Cholleti, A.; Frye, L. L.; Greenwood, J. R.; Timlin, M. R.; Uchimaya, M. Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules J. Comput.-Aided Mol. Des. 2007, 21, 681-691 10.1007/s10822-007-9133-z
26. Christiansen, E.; Hansen, S. V. F.; Urban, C.; Hudson, B. D.; Wargent, E. T.; Grundmann, M.; Jenkins, L.; Zaibi, M.; Stocker, C. J.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Milligan, G.; Cawthorne, M. A.; Ulven, T. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes ACS Med. Chem. Lett. 2013, 4, 441-445 10.1021/ml4000673
27. Sun, P.; Wang, T.; Zhou, Y.; Liu, H.; Jiang, H.; Zhu, W.; Wang, H. DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic beta-Cells dysfunction in db/db mice PLoS One 2013, 8, e66744 10.1371/journal.pone.0066744
28. Zhang, X. D.; Yan, G. R.; Li, Y. M.; Zhu, W. L.; Wang, H. Y. DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats Biomed. Pharmacother. 2010, 64, 647-651 10.1016/j.biopha.2010.06.008
29. Taneera, J.; Lang, S.; Sharma, A.; Fadista, J.; Zhou, Y.; Ahlqvist, E.; Jonsson, A.; Lyssenko, V.; Vikman, P.; Hansson, O.; Parikh, H.; Korsgren, O.; Soni, A.; Krus, U.; Zhang, E.; Jing, X. J.; Esguerra, J. L.; Wollheim, C. B.; Salehi, A.; Rosengren, A.; Renstrom, E.; Groop, L. A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets Cell Metab. 2012, 16, 122-134 10.1016/j.cmet.2012.06.006
30. Vestmar, M. A.; Andersson, E. A.; Christensen, C. R.; Hauge, M.; Glumer, C.; Linneberg, A.; Witte, D. R.; Jorgensen, M. E.; Christensen, C.; Brandslund, I.; Lauritzen, T.; Pedersen, O.; Holst, B.; Grarup, N.; Schwartz, T. W.; Hansen, T. Functional and genetic epidemiological characterisation of the FFAR4 (GPR120) p.R270H variant in the Danish population J. Med. Genet. 2016, 53, 616 10.1136/jmedgenet-2015-103728
31. 2 adrenoceptor Nature 2011, 469, 175-180 10.1038/nature09648
32. Sali, A.; Blundell, T. L. Comparative Protein Modeling by Satisfaction of Spatial Restraints J. Mol. Biol. 1993, 234, 779-815 10.1006/jmbi.1993.1626
33. Kundu, N. G.; Khan, M. W.; Mukhopadhyay, R. Heteroannulation through combined palladium catalysed and friedel-crafts reactions strategy: Synthesis of 3-alkylidene isoiodolin-1-ones Tetrahedron 1999, 55, 12361-12376 10.1016/S0040-4020(99)00719-X
34. Olsson, M. H.; Sondergaard, C. R.; Rostkowski, M.; Jensen, J. H. PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions J. Chem. Theory Comput. 2011, 7, 525-537 10.1021/ct100578z
35. Schrödinger Release 2015-3: MacroModel, version 10.9; Schrödinger, LLC: New York, 2015.
36. Schrödinger Release 2015-3: LigPrep, version 3.5; Schrödinger, LLC: New York, 2015.
37. Kang, S. K.; Ryu, H. C.; Lee, S. W. Ni(acac)(2)-catalyzed cross-coupling and carbonylative cross-coupling of organostannanes with hypervalent iodonium salts J. Chem. Soc., Perkin Trans. 1 1999, 2661-2663 10.1039/a906086c
38. Cho, C. S.; Oh, B. H.; Shim, S. C. Synthesis of quinolines by ruthenium-catalyzed heteroannulation of anilines with 3-amino-1-propanol J. Heterocycl. Chem. 1999, 36, 1175-1178 10.1002/jhet.5570360510
39. Wargent, E. T.; Zaibi, M. S.; O'Dowd, J. F.; Cawthorne, M. A.; Wang, S. J.; Arch, J. R.; Stocker, C. J. Evidence from studies in rodents and in isolated adipocytes that agonists of the chemerin receptor CMKLR1 may be beneficial in the treatment of type 2 diabetes PeerJ 2015, 3, e753 10.7717/peerj.753